|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||386.44484 g/mol g·mol−1|
|3D model (JSmol)|
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|